A Study of ST-1898 for Unresectable or Metastatic Melanoma
A phase 1/2 trial of ST-1898 tablets in melanoma, run by Beijing Scitech-Mq Pharmaceuticals Limited, now recruiting.
Overview
A Study of ST-1898 for Unresectable or Metastatic Melanoma is a phase 1/2 interventional study registered as NCT06359860 by Beijing Scitech-Mq Pharmaceuticals Limited, with 64 participants planned, started 2023-11-07 and due to reach its primary completion in 2026-12. Interventions recorded: ST-1898 tablets.
Similar pages
not linked directly; found by shared links- TrialStudy of ST-1898 in Advanced Renal Cell Carcinoma
Shares Beijing Scitech-Mq Pharmaceuticals and the tag pipeline.
- TrialStudy of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer
Shares Beijing Scitech-Mq Pharmaceuticals and the tag pipeline.
- TrialPhase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors
Shares Melanoma and the tag pipeline.
- TrialIntratumoral N17350 in Advanced Solid Tumors
Shares Melanoma and the tag pipeline.
- TrialNeoadjuvant L19IL2/L19TNF- Pivotal Study
Shares Melanoma and the tag pipeline.
- TrialEfficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
Shares Melanoma and the tag pipeline.
- TrialAMT-253 in Patients With Advanced Solid Tumours
Shares Melanoma and the tag pipeline.
- TrialSCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)
Shares Melanoma and the tag pipeline.